| Literature DB >> 24723815 |
N S Ahmed1, K O Alfooty2, S S Khalifah2.
Abstract
Novel Schiff's bases 4a-e, 5a, 5b, and 6, thiazolidine 7a-d, and pyrazolidine 8 have been synthesized using the versatile synthon 4-hydroxy-2,7-dimethyl-1,8-naphthyridine 1. Reactions carried out under ultrasound irradiation showed higher rates and yields than those done under silent conditions. The newly synthesized compounds were evaluated for HepG2 cell growth inhibition. The results obtained revealed that the tested compounds possess inhibitory effect on the growth of HepG2 liver cancer cells. The results were compared to doxorubicin as a reference drug (IC50: 0.04). Compounds 4a and 7b showed the highest inhibition activity against the HepG2 cell line (IC50: 0.047 and 0.041 µM, resp.) among all the tested compounds.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24723815 PMCID: PMC3956519 DOI: 10.1155/2014/587059
Source DB: PubMed Journal: ScientificWorldJournal ISSN: 1537-744X
Figure 1Vosaroxin.
Scheme 1
Scheme 2
Figure 2Synthesis of Schiff's bases derivatives 4a–e, 5a, 5b, and 6 both under ultrasonic irradiation and using the conventional method.
| Compound | Ultrasonic irradiation | Conventional | ||
|---|---|---|---|---|
| Time (min.) | Yield % | Time (h) | Yield % | |
|
| 15 | 98 | 1 | 97 |
|
| 30 | 93 | 2 | 91 |
|
| 30 | 93 | 2 | 91 |
|
| 20 | 96 | 2 | 94 |
|
| 30 | 93 | 3 | 92 |
|
| 40 | 95 | 6 | 93 |
|
| 40 | 91 | 8 | 88 |
|
| 10 | 98 | 1 | 96 |
Scheme 3Synthesis of 4-oxothiazolidine derivatives (7a–d) under catalyzed ultrasonic irradiation, uncatalyzed ultrasonic irradiation, and using the conventional method.
| Compound | Catalyzed ultrasonic irradiation | Uncatalyzed ultrasonic irradiation | Conventional | |||
|---|---|---|---|---|---|---|
| Time (min) | Yield % | Time (min) | Yield % | Time (h) | Yield % | |
|
| 40 | 90 | 100 | 43 | 36 | 40 |
|
| 60 | 89 | 100 | 51 | 44 | 43 |
|
| 40 | 93 | 85 | 47 | 48 | 44 |
|
| 65 | 92 | 90 | 56 | 39 | 49 |
Cytotoxic activity of the newly synthesized selected derivatives on the liver HepG2 cancer cell line in comparison to the traditional anticancer drug DOX.
| Compounds | IC50 ( |
|---|---|
|
| 0.086 |
|
| 0.047 |
|
| 0.057 |
|
| 0.094 |
|
| 0.053 |
|
| 0.052 |
|
| 0.041 |
|
| 0.053 |
|
| 0.049 |
| DOX | 0.040 |